A 64 Cu‐Labeled Oxopurine Derivative for Translocator Protein–Targeted Inflammation Imaging
Journal of Labelled Compounds and Radiopharmaceuticals · 2026-06 · 69 (7-8)
DOI: 10.1002/jlcr.70032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Labelled Compounds and Radiopharmaceuticals, online erschienen am 02.06.2026. Verfasst von Undram Ochirsukh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Applied RI, Korea Institute of Radiological & Medical Sciences (KIRAMS), Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Copper Radioisotopes, Inflammation, Receptors, GABA. Die Arbeit nennt 42 Literaturangaben. Gefördert von: Korea Institute of Radiological & Medical Sciences (KIRAMS), Korea Institute of Radiological and Medical Sciences.
Abstract (Originalsprache)
The translocator protein (TSPO) is a mitochondrial biomarker overexpressed in activated immune cells and various tumors that is an attractive target for positron emission tomography (PET) imaging of inflammation and the tumor microenvironment. We designed and evaluated the novel TSPO‐targeted PET tracer, 64 Cu‐purine ([ 64 Cu] 5 ), constructed from a purine scaffold conjugated to a NOTA chelator. Molecular docking analysis indicated that the DOTA analog exhibited slightly higher TSPO binding affinity than did the NOTA derivative; however, the NOTA chelator was selected for 64 Cu labeling due to its superior radiochemical yield and stability. [ 64 Cu] 5 demonstrated high radiochemical purity, excellent in vitro and in vivo stability, and moderate lipophilicity, which minimized nonspecific uptake. In vitro, [ 64 Cu] 5 showed significantly higher uptake in inflammatory macrophages than in tumor cells. In vivo PET imaging and biodistribution studies revealed preferential accumulation in inflamed and tumor tissues, with reduced uptake following PK11195 administration. Autoradiography and immunohistochemistry confirmed tracer accumulation in both inflamed and tumor tissues, reflecting the presence of inflammation within the tumor microenvironment. Overall, these findings suggest that [ 64 Cu] 5 is a promising TSPO‐targeting PET radiotracer for imaging inflammation‐associated processes in tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Applied RI, Korea Institute of Radiological & Medical Sciences (KIRAMS), Seoul, Republic of Korea.
- Graduate School of Medical Science (SeoulTech-KIRAMS), Seoul National University of Science and Technology, Seoul, Republic of Korea.
- Radiological and Medico-Oncological Sciences, University of Science and Technology (UST), Daejeon, Republic of Korea.
ORCID-Profile: Ji-Ae Park
Förderung
- Korea Institute of Radiological & Medical Sciences (KIRAMS)
- Korea Institute of Radiological and Medical Sciences
Zitieren
APA
Ochirsukh, U., Bibi, I., Kim, H. Y., Ko, I. O., Kang, K. J., Lee, H. J., Kim, K. I., Park, J. A., & Kim, J. Y. (2026). A 64 Cu‐Labeled Oxopurine Derivative for Translocator Protein–Targeted Inflammation Imaging. Journal of Labelled Compounds and Radiopharmaceuticals, 69(7-8). https://doi.org/10.1002/jlcr.70032
Vancouver
Ochirsukh U, Bibi I, Kim HY, Ko IO, Kang KJ, Lee HJ, et al. A 64 Cu‐Labeled Oxopurine Derivative for Translocator Protein–Targeted Inflammation Imaging. Journal of Labelled Compounds and Radiopharmaceuticals. 2026;69(7-8). doi:10.1002/jlcr.70032
BibTeX
@article{Ochirsukh2026,
author = {Ochirsukh, Undram and Bibi, Iqra and Kim, Ho Young and Ko, In Ok and Kang, Kyung Jun and Lee, Hyun Ji and Kim, Kwang Il and Park, Ji-Ae and Kim, Jung Young},
title = {A 64 Cu‐Labeled Oxopurine Derivative for Translocator Protein–Targeted Inflammation Imaging},
journal = {Journal of Labelled Compounds and Radiopharmaceuticals},
year = {2026},
volume = {69},
number = {7-8},
doi = {10.1002/jlcr.70032}
}
EUVIMED